Search SAMHSA Publications and Digital Products
Store Facets Summary
- Clear all filters
- Remove Public Health Professionals
- Remove People with Substance Use or Abuse Problems as Audience
- Remove People with Substance Use or Abuse Problems as Population Group
- Remove Mature Adults as Population Group
- Remove Substance Abuse
- Remove Pain Relievers
- Remove Marijuana
- Remove Heroin
- Remove Medication-Assisted Treatment
Main page content
Published: August 2021
The Executive Summary of this Treatment Improvement Protocol provides an overview on the use of the three Food and Drug Administration-approved medications used to treat opioid use disorder—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery.
Published: July 2021
This Treatment Improvement Protocol (TIP) reviews the use of the three Food and Drug Administration (FDA)-approved medications used to treat OUD—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery for people with OUD. This is a revision.
Published: December 2019
This guide supports health care providers, systems, and communities seeking to prevent marijuana use by pregnant women. It describes relevant research findings, examines emerging and best practices, identifies knowledge gaps and implementation challenges, and offers useful resources.
Published: June 2017
This report presents national data about the prevalence of behavioral health conditions. This data includes the rate of serious mental illness, suicidal thoughts, substance use, and underage drinking. The report also highlights the percentages of those who seek treatment for these conditions. The state-level Barometers contain valuable insight into the behavioral health needs and the unique challenges faced by communities across the country. This analysis can help public health authorities and others determine the best ways of meeting behavioral health care needs and disparities among various communities.